Stefano Aliberti

Q: What Schools Are Affiliated With Stefano Aliberti

Stefano Aliberti is affiliated with the following schools: University of Milan, University of Louisville, Humanitas University, University of Milano-Bicocca, University of Bologna

Stefano Aliberti's AcademicInfluence.com Rankings

Stefano Aliberti

Biology

#12532

World Rank

#16014

Historical Rank

Biotechnology

#222

World Rank

#224

Historical Rank

Microbiology

#749

World Rank

#823

Historical Rank

Immunology

#837

World Rank

#860

Historical Rank

biology Degrees

Download Badge

Biology

Stefano Aliberti's Degrees

PhD Biomedical Sciences University of Milan
Masters Biotechnology University of Milan
Bachelors Biology University of Milan

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Stefano Aliberti Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stefano Aliberti's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genomewide Association Study of Severe Covid-19 with Respiratory Failure (2020) (1425)
The bronchiectasis severity index. An international derivation and validation study. (2014) (691)
European Respiratory Society guidelines for the management of adult bronchiectasis (2017) (684)
Towards tuberculosis elimination: an action framework for low-incidence countries (2015) (656)
Mapping the human genetic architecture of COVID-19 (2021) (455)
Pulmonary fibrosis secondary to COVID-19: a call to arms? (2020) (386)
Lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia: a prospective, multicenter, diagnostic accuracy study. (2012) (363)
A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. (2015) (292)
Management of bronchiectasis in adults (2015) (227)
Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. (2015) (222)
Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research (2017) (221)
Clinical phenotypes in adult patients with bronchiectasis (2016) (203)
Complement activation in patients with COVID-19: A novel therapeutic target (2020) (201)
Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. (2016) (190)
Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. (2012) (184)
Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. (2008) (174)
Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration (2016) (171)
Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. (2013) (167)
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial (2021) (167)
Characterization of the “Frequent Exacerbator Phenotype” in Bronchiectasis (2018) (167)
Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. (2013) (161)
Chlamydophila pneumoniae. (2020) (144)
The EMBARC European Bronchiectasis Registry: protocol for an international observational study (2016) (144)
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline (2021) (138)
The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis (2018) (134)
Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. (2010) (133)
Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia (2014) (131)
Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. (2019) (128)
Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts (2016) (126)
The ADAMTS13‐von Willebrand factor axis in COVID‐19 patients (2020) (123)
Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective (2013) (119)
Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. (2008) (115)
Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study (2020) (114)
The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions (2018) (111)
Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients (2018) (98)
Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling (2017) (95)
Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. (2010) (94)
The management of community-acquired pneumonia in the elderly. (2014) (93)
Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. (2016) (93)
The role of lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. (2012) (92)
COVID-19 in pregnant women: A systematic review and meta-analysis (2020) (91)
The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients (2014) (91)
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis (2021) (83)
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study (2020) (79)
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients (2018) (78)
Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices (2016) (74)
Noninvasive Ventilatory Support of Patients with COVID-19 outside the Intensive Care Units (WARd-COVID) (2021) (74)
Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. (2010) (71)
Neutrophil elastase in bronchiectasis (2017) (68)
Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis: A Multicenter Cohort Study (2017) (67)
Use of anakinra in severe COVID-19: A case report (2020) (66)
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis (2015) (66)
Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. (2016) (65)
Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infection (2008) (64)
ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update (2018) (63)
Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia. (2011) (63)
Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients. (2021) (61)
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia (2009) (61)
Risk Factors for Noninvasive Ventilation Failure in Critically Ill Subjects With Confirmed Influenza Infection (2017) (60)
Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis (2016) (60)
QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. (2019) (57)
Integrative microbiomics in bronchiectasis exacerbations (2021) (54)
Compliance with anti-H1N1 vaccine among healthcare workers and general population. (2012) (52)
“Management of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies” (2020) (51)
The role of vaccination in preventing pneumococcal disease in adults. (2014) (51)
Standardised classification of the aetiology of bronchiectasis using an objective algorithm (2017) (50)
Prone and Lateral Positioning in Spontaneously Breathing Patients With COVID-19 Pneumonia Undergoing Noninvasive Helmet CPAP Treatment (2020) (49)
Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. (2016) (48)
Prognostic and Pathogenic Role of Angiopoietin‐1 and ‐2 in Pneumonia (2018) (48)
Cardiac diseases complicating community-acquired pneumonia (2014) (47)
Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. (2021) (47)
Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia (2014) (47)
The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients (2020) (47)
Management of nontuberculous mycobacterial infection in the elderly. (2014) (45)
Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis (2014) (44)
The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. (2014) (43)
Noninvasive respiratory support outside the intensive care unit for acute respiratory failure related to coronavirus-19 disease: a systematic review and meta-analysis (2021) (41)
Strategic Targets of Essential Host-Pathogen Interactions (2005) (41)
Criteria for clinical stability in hospitalised patients with community-acquired pneumonia (2012) (40)
The BRICS (Bronchiectasis Radiologically Indexed CT Score): A Multicenter Study Score for Use in Idiopathic and Postinfective Bronchiectasis (2017) (40)
COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity? (2014) (40)
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation (2014) (40)
A comprehensive approach to lung function in bronchiectasis. (2018) (40)
De-escalation therapy among bacteraemic patients with community-acquired pneumonia. (2015) (39)
Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. (2011) (37)
From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis (2020) (37)
A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation (2019) (37)
Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study. (2018) (35)
Chlamydia pneumoniae and Mycoplasma pneumoniae. (2005) (35)
Early Phases of COVID-19 Are Characterized by a Reduction in Lymphocyte Populations and the Presence of Atypical Monocytes (2020) (34)
Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases (2014) (34)
Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes. (2013) (33)
Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) (2020) (33)
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. (2021) (33)
Antibiotics as immunomodulant agents in COPD. (2012) (32)
Quality standards for the management of bronchiectasis in Italy: a national audit (2016) (32)
The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis (2017) (32)
Non-Intensive Care Unit Acquired Pneumonia: A New Clinical Entity? (2016) (32)
Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective (2018) (32)
Pneumococcal vaccine and patients with pulmonary diseases. (2014) (32)
Failure to conceive in women with CF is associated with pancreatic insufficiency and advancing age. (2019) (31)
The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration (2017) (31)
The biology of pulmonary exacerbations in bronchiectasis (2019) (30)
Hemostatic alterations in COVID-19 (2020) (30)
A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections. (2020) (30)
Bronchiectasis and Aspergillus: How are they linked? (2017) (30)
Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia (2015) (29)
Multidrug-resistant pathogens in patients with pneumonia coming from the community (2016) (28)
Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19 (2021) (28)
Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis (2020) (28)
Chlamydophila pneumoniae induces a sustained airway hyperresponsiveness and inflammation in mice (2007) (28)
A systematic review on the impact of appropriate versus inappropriate initial antibiotic therapy on the outcomes of patients with severe bacterial infections. (2020) (27)
International prevalence and risk factors evaluation for Drug-Resistant Streptococcus pneumoniae pneumonia. (2019) (27)
The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. (2016) (27)
Microbiological Diagnosis and Antibiotic Therapy in Patients with Community-Acquired Pneumonia and Acute COPD Exacerbation in Daily Clinical Practice: Comparison to Current Guidelines (2013) (27)
Early phases of COVID-19 are characterized by a reduction of lymphocyte populations and the presence of atypical monocytes (2020) (26)
Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees (2016) (26)
Antimicrobial peptides, disease severity and exacerbations in bronchiectasis (2019) (26)
Prevalence and incidence of bronchiectasis in Italy (2020) (26)
The Changing Microbiologic Epidemiology of Community-Acquired Pneumonia (2013) (26)
Blood eosinophils predict inhaled fluticasone response in bronchiectasis (2020) (25)
How to Process Sputum Samples and Extract Bacterial DNA for Microbiota Analysis (2018) (24)
Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. (2011) (24)
In vitro activity of N-acetylcysteine against Stenotrophomonas maltophilia and Burkholderia cepacia complex grown in planktonic phase and biofilm (2018) (24)
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study (2018) (24)
Challenges in the development of new therapies for bronchiectasis (2015) (24)
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) (2020) (24)
COVID‐19 in lung transplant recipients: A case series from Milan, Italy (2020) (24)
Hospital Admission Decision for Patients with Community-Acquired Pneumonia (2013) (23)
COVID-19 multidisciplinary high dependency unit: the Milan model (2020) (23)
Deep vein thrombosis in COVID-19 patients in general wards: prevalence and association with clinical and laboratory variables (2021) (23)
Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network (2018) (22)
Characterisation of Eosinophilic Bronchiectasis: A European Multicohort Study. (2022) (22)
Delirium symptoms during hospitalization predict long-term mortality in patients with severe pneumonia (2014) (22)
Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis (2018) (22)
An international perspective on hospitalized patients with viral community-acquired pneumonia (2018) (22)
Prognostic parameters of in‐hospital mortality in COVID‐19 patients—An Italian experience (2021) (22)
Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium. (2015) (21)
Clinical applications of azithromycin microspheres in respiratory tract infections (2007) (21)
Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia (2019) (21)
The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) ERS Clinical Research Collaboration (2018) (21)
Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRIs project (2017) (21)
Treatment of Community-Acquired Pneumonia in Immunocompromised Adults (2020) (20)
Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response (2022) (19)
Clinical Stability versus Clinical Failure in Patients with Community-Acquired Pneumonia (2012) (19)
Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia (2013) (19)
Characterization of bronchiectasis in the elderly. (2016) (19)
SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity (2021) (19)
Azithromycin and lower respiratory tract infections (2005) (19)
Non-invasive positive pressure ventilation in pneumonia outside Intensive Care Unit: An Italian multicenter observational study. (2019) (18)
The role of biomarkers in low respiratory tract infections. (2012) (18)
In Vitro Synergism of Colistin and N-acetylcysteine against Stenotrophomonas maltophilia (2019) (18)
Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis (2018) (18)
Pneumonia is a neglected problem: it is now time to act. (2019) (18)
Acidemia does not affect outcomes of patients with acute cardiogenic pulmonary edema treated with continuous positive airway pressure (2010) (17)
Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression. (2020) (17)
Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound? (2020) (17)
A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults (2019) (16)
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline (2022) (16)
How to choose the duration of antibiotic therapy in patients with pneumonia (2015) (16)
The Relationship Between Symptoms, Exacerbations and Treatment Response in Bronchiectasis. (2020) (16)
Management of Acute Respiratory Failure Due to Community-Acquired Pneumonia: A Systematic Review (2019) (16)
Prevalence, risk factors and outcomes of patients coming from the community with sepsis due to multidrug resistant bacteria (2019) (16)
Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy (2020) (15)
Role of inhaled corticosteroids in reducing exacerbations in bronchiectasis patients with blood eosinophilia pooled post-hoc analysis of 2 randomized clinical trials. (2020) (15)
Repeteability of Circulating Eosinophil Measures and Inhaled Corticosteroids Effect in Bronchiectasis. A Post Hoc Analysis of a Randomized Clinical Trial. (2020) (15)
Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement (2018) (15)
Chest physiotherapy in European patients with bronchiectasis: Data from the EMBARC registry (2017) (15)
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients (2020) (15)
Nontuberculous Mycobacteria: Epidemiologic, Mycobacteriologic, and Clinical Aspects (2015) (15)
[Pneumococcal vaccination in adults: recommendations from the Italian Society of Respiratory Medicine (SIMeR) and the Italian Society of Hygiene, Preventive Medicine and Public Health (SItI)]. (2014) (15)
Mortality in acute cardiogenic pulmonary edema treated with continuous positive airway pressure (2009) (15)
100 years of respiratory medicine: pneumonia. (2007) (15)
Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. (2006) (14)
Aspiration risk factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia. (2020) (14)
Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study (2020) (14)
Comparison of different conditions for DNA extraction in sputum - a pilot study (2019) (14)
Chest X-ray findings in a large cohort of 1117 patients with SARS-CoV-2 infection: a multicenter study during COVID-19 outbreak in Italy (2020) (13)
Detailed stratified GWAS analysis for severe COVID-19 in four European populations (2022) (13)
Role of Streptococcus pneumoniae infection in chronic obstructive pulmonary disease patients in Italy (2017) (13)
Empirical Coverage of Methicillin-Resistant Staphylococcus aureus in Community-Acquired Pneumonia: Those Who Do Not Remember the Past Are Doomed to Repeat It. (2016) (13)
Investigating the Etiology of Bronchiectasis: You Do Not Find What You Do Not Look For (2017) (13)
A CLUSTER ANALYSIS OF BRONCHIECTASIS PATIENTS BASED ON THE AIRWAY IMMUNE PROFILE. (2020) (13)
Diaphragm ultrasonography in the management of patients with amyotrophic lateral sclerosis (2013) (13)
New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations (2021) (13)
In vitro synergism of colistin in combination with N-acetylcysteine against Acinetobacter baumannii grown in planktonic phase and in biofilms (2018) (13)
The pneumonia severity index and the CRB-65 in cancer patients with community-acquired pneumonia. (2009) (12)
The ERS Research Agency: the beginning (2016) (12)
Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis (2007) (12)
Individualizing duration of antibiotic therapy in community-acquired pneumonia. (2017) (12)
International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline (2020) (12)
Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study. (2021) (11)
Cardiovascular autonomic alterations in hospitalized patients with community-acquired pneumonia (2016) (11)
Evaluation of active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients: A comparison among different techniques. (2019) (11)
State of the art review: management of bronchiectasis in adults (2015) (11)
Real-life evaluation of clinical outcomes in patients undergoing treatment for non-tuberculous mycobacteria lung disease: A ten-year cohort study. (2020) (11)
The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia. (2009) (11)
Respiratory Mycoses in COPD and Bronchiectasis (2021) (11)
Usefulness of simplified acute physiology score II in predicting mortality in patients admitted to an emergency medicine ward (2009) (11)
Serum Desmosine is Associated with Long-term All-cause and Cardiovascular Mortality in Bronchiectasis. (2020) (10)
Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study. (2017) (10)
Phenotype characterization of non-cystic fibrosis bronchiectasis in India (2017) (10)
Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care (2016) (10)
Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study (2016) (10)
Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics (2021) (10)
Mixed community-acquired lower respiratory tract infections (2007) (10)
The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol (2018) (10)
A real life evaluation of non invasive ventilation in acute cardiogenic pulmonary edema: a multicenter, perspective, observational study for the ACPE SIMEU study group (2018) (10)
Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study (2020) (9)
S124 Derivation and validation of the bronchiectasis severity index: an international multicentre observational study (2013) (9)
High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis (2017) (9)
Sympatho–Vagal Dysfunction in Patients with End-Stage Lung Disease Awaiting Lung Transplantation (2020) (9)
T2-High Endotype and Response to Biological Treatments in Patients with Bronchiectasis (2021) (9)
Assessment of Platelet Thrombus Formation under Flow Conditions in Adult Patients with COVID-19: An Observational Study (2021) (9)
Knowledge and attitudes on influenza vaccination among Italian physicians specialized in respiratory infections: an Italian Respiratory Society (SIP/IRS) web-based survey. (2018) (8)
Pneumonia in the community caused by multidrug-resistant organisms: keep working on probabilistic scores. (2012) (8)
ROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group (2021) (8)
Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation. (2021) (8)
Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST) (2020) (8)
Bronchiectasis as a Long-Term Consequence of SARS-COVID-19 Pneumonia: Future Studies are Needed (2021) (8)
A 13-year-old female with shortness of breath and pleuritic chest pain (2006) (8)
Geriatric multidimensional assessment for elderly patients with acute respiratory diseases. (2014) (8)
Predictors of Helmet CPAP Failure in COVID-19 Pneumonia: A Prospective, Multicenter, and Observational Cohort Study (2022) (8)
An update on the pharmacotherapeutic management of lower respiratory tract infections (2017) (8)
Diagnosis and quantification of bronchiectasis using computed tomography or magnetic resonance imaging: A systematic review. (2020) (7)
Positive end expiratory pressure in acute hypoxemic respiratory failure due to community acquired pneumonia: do we need a personalized approach? (2018) (7)
HDL in COVID-19 Patients: Evidence from an Italian Cross-Sectional Study (2021) (7)
Nasopharyngeal Microbiota Analysis in Healthy and Otitis-prone Children (2020) (7)
Lung recruitability of COVID-19 pneumonia in patients undergoing helmet CPAP (2020) (7)
Introducing a new HERMES project on respiratory infections (2016) (7)
Bronchiectasis: an update (2009) (7)
Serotypes and antibiotic susceptibility of Streptococcus pneumoniae isolated from hospitalized patients with community-acquired pneumonia in Italy (2017) (7)
International perspective on the new 2019 ATS/IDSA CAP guideline – a critical appraisal by a global expert panel (2020) (7)
Small Airway Disease and Emphysema Are Associated with Future Exacerbations in Smokers with CT-derived Bronchiectasis and COPD: Results from the COPDGene Cohort. (2021) (7)
Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey (2020) (7)
Chromogranin A levels and mortality in patients with severe sepsis (2015) (7)
Selection of Candidates for Lung Transplantation: The First Italian Consensus Statement. (2017) (7)
Blood eosinophils do not predict inhaled budesonide response in bronchiectasis (2020) (7)
Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group (2022) (6)
Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry (2020) (6)
The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia (2009) (6)
Healthcare-associated pneumonia: where do we go next? (2014) (6)
The heterogeneity of bronchiectasis patient characteristics, management and outcomes across Europe: Data from the EMBARC registry (2018) (6)
A New SERPINA-1 Missense Mutation Associated with Alpha-1 Antitrypsin Deficiency and Bronchiectasis (2017) (6)
Acute effects of positive end-expiratory pressure on left ventricle diastolic function in healthy subjects (2009) (6)
Community-acquired pneumonia (2014) (6)
Inflammatory molecular endotypes in bronchiectasis (2019) (6)
Management of bronchiectasis in Europe: Data from the European bronchiectasis registry (EMBARC) (2016) (6)
Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease (2022) (6)
When and how ruling out cystic fibrosis in adult patients with bronchiectasis (2018) (6)
Bronchiectasis Rheumatoid Overlap Syndrome(BROS) is an Independent Risk Factor for Mortalityin Patients with Bronchiectasis: A Multicentre CohortStudy (2016) (6)
Creatine combined with branched-chain amino acids supplement in speleological practice : a scientific controlled trial (2005) (5)
Standard operating procedures for tuberculosis care (2017) (5)
Protease–Antiprotease Imbalance in Bronchiectasis (2021) (5)
Chlamydia pneumoniae and acute aortic syndrome: a call for a multi-institutional study. (2008) (5)
Additional important research priorities for bronchiectasis in China (2017) (5)
Repeteability of Circulating Eosinophil Measures and Inhaled Corticosteroids Effect in Bronchiectasis. A Post Hoc Analysis of a Randomized Clinical Trial (2020) (5)
Detection and Classification of Bronchiectasis Through Convolutional Neural Networks (2021) (5)
Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. (2021) (5)
Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment (2021) (5)
Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia (2017) (5)
Drug-resistant pathogens in community-acquired pneumonia (2015) (5)
Safety and feasibility of physiotherapy in ICU-admitted severe COVID-19 patients: an observational study. (2022) (4)
Early application of non-invasive continuous positive airway pressure in acute respiratory distress syndrome due to a drug overdose: a case report (2011) (4)
ESICM LIVES 2016: part three (2016) (4)
Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease (2016) (4)
Determinants of quality of life in bronchiectasis using the quality of life bronchiectasis (QOL-B) questionnaire: data from the EMBARC registry (2018) (4)
Sex differences in bronchiectasis patient characteristics: an analysis of the EMBARC cohort (2018) (4)
Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases (2022) (4)
Get together to increase awareness in bronchiectasis: a report of the 2nd World Bronchiectasis Conference (2018) (4)
Telithromycin in lower respiratory tract infections. (2006) (4)
Variability in access and referral to pulmonary rehabilitation in European bronchiectasis patients enrolled in the EMBARC registry (2018) (4)
Influenza A/H1N1 Severe Pneumonia: Novel Morphocytological Findings in Bronchoalveolar Lavage (2014) (4)
Anti-infectives and the Lung (2017) (4)
Upper Respiratory Tract Microbiome and Otitis Media Intertalk: Lessons from the Literature (2020) (4)
Therapeutic Strategies for COVID-19 Lung Disease in Children (2022) (4)
Beyond pulmonary nontuberculous mycobacteria disease: do extra-pulmonary forms represent an emerging clinical and public health threat? (2017) (4)
Patients’ perspectives on bronchiectasis: findings from a social media listening study (2021) (4)
National Survey on the Management of Adult Bronchiectasis in Belgium (2019) (4)
COVID-19 in Immunocompromised Patients: A Systematic Review (2021) (4)
Characteristics of patients with pulmonary non-tuberculous Mycobacterial infection in bronchiectasis: Data from the EMBARC registry (2018) (4)
Heterogeneity in bronchiectasis service provision in Europe: Baseline data from the European bronchiectasis registry (EMBARC) (2015) (4)
Erratum to: Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia (2014) (4)
Bronchiectasis in patients with alpha1-antitrypsin deficiency: prevalence and characteristics (2016) (4)
Non-invasive continuous positive airway pressure in monolateral lung transplant patient with pneumonia and IPF. (2010) (3)
Lung Recruitability of COVID-19 Pneumonia in Patients Undergoing Helmet CPAP (2020) (3)
Epidemiology of clinical trials of medicines in respiratory diseases in Europe and Italy. (2017) (3)
What is important for people with NTM? An EMBARC-ELF patient survey (2020) (3)
M8 Non-tuberculous mycobacteria testing in bronchiectasis in the UK: data from the EMBARC registry (2019) (3)
Exacerbations of bronchiectasis requiring hospitalization; clinical characteristics and outcomes (2016) (3)
Effects of bilateral lung transplantation on cardiac autonomic modulation and cardiorespiratory coupling: a prospective study (2021) (3)
What is the best technique to extract bacterial DNA from sputum? (2018) (3)
Antibiotic therapy and prophylaxis in COPD (2007) (3)
Predictors of starting antimicrobial treatment in patients with nontuberculous mycobacterial lung disease in the Italian scenario: A SITA GIOVANI-IRENE promoted web-survey. (2021) (3)
The association between gastro-oesophageal reflux and exacerbations of bronchiectasis: data from the EMBARC registry (2017) (3)
Administrative databases and clinical governance: The case of COPD (2019) (3)
Never Let a Good Crisis Go to Waste (2021) (3)
ESICM LIVES 2016: part three : Milan, Italy. 1-5 October 2016. (2016) (3)
Bronchiectasis in 2016: advances in our understanding. (2016) (2)
Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment (2021) (2)
Characterization of bronchiectasis in the elderly (2016) (2)
Anti-MRSA Coverage Overutilization as Empiric Therapy for Hospitalized Patients With Community-Acquired Pneumonia and Healthcare-Associated Pneumonia (2017) (2)
Mapping inflammatory endotypes of bronchiectasis associated with impaired mucociliary clearance (2021) (2)
Antimicrobial peptides and airway bacterial colonization in bronchiectasis (2018) (2)
Is it time for a "pneumo-geriatrician" for frail old patients with respiratory diseases? (2014) (2)
The management of patients with community-acquired pneumonia beyond antibiotic therapy. (2012) (2)
European Respiratory Society statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials (2022) (2)
Bronchiectasis: A pulmonary disease with systemic consequences (2022) (2)
Hospital-acquired pneumonia (2005) (2)
Microbial Dysregulation of the 'Lung-Gut' Axis in High-Risk Bronchiectasis (2021) (2)
Cardiovascular side-effects of common antibiotics (2020) (2)
A distinct metabolic profile associated with a fatal outcome in COVID-19 patients during early epidemic in Italy (2021) (2)
Bronchiectasis as a Long-Term Consequence of SARS-COVID-19 Pneumonia: Future Studies are Needed (2021) (2)
The Isoform GC1f of the Vitamin D Binding Protein Is Associated with Bronchiectasis Severity (2021) (2)
Microbial Dysregulation of the Gut-Lung Axis in Bronchiectasis (2022) (2)
Diagnosis and Initial Investigation of Bronchiectasis (2021) (2)
Impact of bronchiectasis on severe asthma: data from the “Severe Asthma Network Italy” (SANI) registry (2018) (2)
Non-invasive continuous positive airway pressure versus oxygen venturi in severe acute respiratory failure due to pneumonia: A randomized controlled trial (2013) (2)
Bacteremic pneumococcal pneumonia is associated with an increased rate of cardiovascular events (2019) (2)
Antiplatelets Improve Survival Among Critically Ill Mechanically Ventilated Patients (2014) (2)
Late Breaking Abstract - The prevalence and burden of Pseudomonas aeruginosa among bronchiectasis patients in Europe- data from the FRIENDS cohort (2017) (2)
Where are the acutely ill best cared for and who should look after them? (2011) (2)
Cortical and subcortical grey matter morphometry for neuroprognostication after cardiac arrest (2016) (2)
Short Duration of Antibiotic Therapy in Hospitalized Patients with Community-Acquired Pneumonia: Results from the CAPO International Cohort Study (2017) (2)
Airway clearance techniques in patients with bronchiectasis. Data from the EMBARC Registry (2020) (2)
Pharmacotherapeutic management of bronchial infections in adults: non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease (2020) (2)
Heparin Binding Protein in sputum compromises epithelial defence and relates to bronchiectasis severity (2019) (2)
Noninvasive ventilation or continuous positive airway pressure in pulmonary edema patients with respiratory acidosis? Look at the bicarbonates (2011) (2)
Early outcomes in CAP: Clinical stability, clinical failure and nonresolving pneumonia (2014) (2)
Distinct Metabolic Profile Associated with a Fatal Outcome in COVID-19 Patients during the Early Epidemic in Italy (2021) (2)
P217 Cystic fibrosis with pancreatic insufficiency is associated with a high incidence of subfertility in women (2018) (2)
Impact of age and comorbidity on presentation, aetiology and outcome in patients with community-acquired pneumonia (2012) (2)
What is important for people with nontuberculous mycobacterial disease? An EMBARC-ELF patient survey (2020) (2)
European Respiratory Monograph : Community-Acquired Pneumonia (2014) (2)
Is it feasible to radiologically monitor the evolution of non‐CF bronchiectasis? (2016) (2)
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia (2023) (2)
Respiratory research networks in Europe and beyond: aims, achievements and aspirations for the 21st century (2017) (2)
Long-Term Domiciliary High-Flow Nasal Therapy in Patients with Bronchiectasis: A Preliminary Retrospective Observational Case-Control Study (2022) (2)
Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report (2018) (2)
Innate and Adaptive Lymphocytes in Non-Tuberculous Mycobacteria Lung Disease: A Review (2022) (2)
New isolation of non-tuberculous mycobacteria in patients with bronchiectasis - data from the European Bronchiectasis Registry (EMBARC) (2019) (2)
Site of care and multidisciplinary approach (2018) (2)
Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry (2022) (1)
Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). (2023) (1)
Analysis of the role of Chest X-Ray in a large cohort of 1117 patients with SARS-CoV-2 infection: an Italian multicenter study (2020) (1)
Respiratory viruses in stable state bronchiectasis (2019) (1)
A pathway to keep all lifelong learners up to date: the ERS continuing professional development programme (2020) (1)
The best of respiratory infections from the 2015 European Respiratory Society International Congress (2016) (1)
Basic (PS01–PS58) (2012) (1)
Impact of cough on insomnia and sleep quality in bronchiectasis (2020) (1)
Determinants of survival in the European Bronchiectasis Registry(EMBARC) (2019) (1)
“Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.” James D. Chalmers, Megan L. Crichton, Pieter C. Goeminne, et al. Eur Respir J 2021; 57: 2100048. (2022) (1)
Cardiac autonomic alterations impact early and late outcomes in patients with community-acquired pneumonia (2013) (1)
Neutrophil Extracellular Traps are Increased in Severe Bronchiectasis and Reduced by Long-Term Azithromycin Treatment (2020) (1)
Asthma as a co-morbidity and cause of bronchiectasis: data from the European Bronchiectasis Registry (EMBARC) (2020) (1)
Acute Improvements of Oxygenation with Cpap and Clinical Outcomes in Severe COVID-19 Pneumonia: A Multicenter, Retrospective Study (2022) (1)
How to Identify Causes and Predisposing Factors in Bronchiectasis (2018) (1)
An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP) (2011) (1)
Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study (2020) (1)
Clinical phenotypes in bronchiectasis: right on track to develop precision medicine in respiratory diseases. (2016) (1)
Immunodeficiency associated bronchiectasis in the European Bronchiectasis Registry (EMBARC) (2020) (1)
Validation of AMP-Activated Protein Kinase as a Therapeutic Target in Bronchiectasis (2020) (1)
Diagnosis and management of patients with α1-antitrypsin deficiency: an Italian perspective (2022) (1)
Corrigendum to "De-escalation therapy among bacteraemic patients with community-acquired pneumonia" [Clin Microbiol Infect 21 (2015) 936.e11-936.e18] (2015) (1)
Vaccinazione antipneumococcica negli adulti : raccomandazioni della Società italiana di medicina respiratoria (SIMeR) e della Società italiana di igiene, medicina preventiva e sanità pubblica (SItI) = Pneumococcal vaccination in adults: recommendations from the Italian society of respiratory medicin (2014) (1)
Rheumatoid arthritis is a common and important comorbidity in bronchiectasis: Data from the EMBARC European bronchiectasis registry (2016) (1)
Risk factors for new P. aeruginosa isolation in bronchiectasis- data from the European Bronchiectasis Registry (EMBARC) (2019) (1)
Impact of Inflammatory bowel disease in bronchiectasis (IBD-BR) data from the EMBARC registry (2018) (1)
University of Dundee Comorbidities and the risk of mortality in patients with bronchiectasis (2016) (1)
Alpha-1 antitrypsin deficiency in patients with bronchiectasis: data from the European Bronchiectasis Registry EMBARC (2020) (1)
Comparison of different sets of immunological tests to identify treatable immunodeficiencies in adult bronchiectasis patients (2021) (1)
Development of antibiotic-resistance in P. aeruginosa obtained from bronchiectasis patients: a multicenter prospective observational study (2018) (1)
Patients in randomized clinical trials of bronchiectasis are only partially representative of clinical practice: A European cohort study (2015) (1)
ERS guideline compliant antibiotics among hospitalized patients with Community-acquired pneumonia on the ward service (2018) (1)
Bacterial Etiology of Community-Acquired Pneumonia and Appropriateness of Empirical Treatment Recommendations: An International Observational Cohort Study (2019) (1)
Rhinosinusitis is associated with increased symptoms and more frequent exacerbations among patients with bronchiectasis- data from the EMBARC registry (2018) (1)
Validation of MRSA Specific Scoring Systems Among Hospitalized Patients with CAP (2019) (1)
Respiratory viruses in stable bronchiectasis: A multicenter evaluation in Northern Italy. (2022) (1)
Desmosine is a predictor of long-term cardiovascular mortality in bronchiectasis (2020) (1)
Treatable traits in interstitial lung diseases: a call to action. (2023) (1)
Differences between local and systemic inflammatory response in patients with community acquired pneumonia (CAP) (2011) (1)
PX-3 Comparison of two automated tests for the serological evaluation of rubella and cytomegalovirus infection (2009) (0)
Dyspnea in crackling lungs. (2014) (0)
Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia (2020) (0)
Prevalence of S. pneumoniae colonization and serotypes in sputum of vaccine-naive adults with cystic fibrosis (2019) (0)
Hepatic and pulmonary involvement in a patient with PR3-ANCA vasculitis following SARS-CoV-2 vaccination: a case report. (2023) (0)
Clinical and economical impact of exacerbations of chronic obstructive pulmonary disease (COPD): A two-year study (2011) (0)
The Etiological Screening of Bronchiectasis (2022) (0)
Correction to: Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study (2021) (0)
Preventing arterial catheter-associated bloodstream infections: common sense and chlorhexidine. (2014) (0)
Epidemiology of clinical trials in respiratory diseases in Europe and Italy (2015) (0)
O papel da neutropenia no prognóstico do doente oncológico com pneumonia adquirida na comunidade**Eur Respir J 2009; 33:142-147 (2009) (0)
2019 ATS/IDSA CRITERIA TO IDENTIFY P. AERUGINOSA AND MRSA PROMOTE OVERUTILIZATION OF MRSA THERAPY IN NON-SEVERE CAP (2020) (0)
Chest Physiotherapy in patients with Bronchiectasis – what is the current practice in Europe? (2018) (0)
The journey to bronchiectasis diagnosis and care: an EMBARC/ELF patient survey (2021) (0)
Validity of COPD diagnosis in Bronchiectasis patients: data from the EMBARC registry (2018) (0)
The weight of radiological severity in patients with non-CF bronchiectasis (2014) (0)
Non-invasive-ventilation in H1N1 acute respiratory failure in emergency department: A case series (2011) (0)
Epidemiology and factors associated with overweight in adults with cystic fibrosis: an Italian multicenter experience (2020) (0)
Endotyping bronchiectasis through multi-omic profiling (2020) (0)
MRSA specific scores promote overuse of anti-MRSA antibiotics (2019) (0)
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia (2023) (0)
Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia (2020) (0)
Are multi-drug resistant (MDR) pathogens related to higher mortality in pneumonia? (2011) (0)
Synergistic activity of colistin in combination with N-acetylcysteine against colistin-resistant Acinetobacter Baumannii grown in biofilms (2018) (0)
Biologics in Bronchiectasis: A Future Treatment? (2022) (0)
Severity scores do not accurately predict microbial aetiology in community-acquired pneumonia (2013) (0)
Prevalence and serotyping of S. pneumoniae in a large vaccine-naive cohort of adults with cystic fibrosis (2021) (0)
Chlamydia Pneumoniae and Acute Aortic Syndrome: A Call for a Multi-Institutional Study Clamidia Pneumoniae e Sindromi aortiche acute: necessità di uno studio multicentrico (2008) (0)
Genetic and Serum Screening for Alpha-1-Antitrypsin Deficiency in Adult Patients with Cystic Fibrosis: A Single-Center Experience (2022) (0)
Respiratory viruses in adults with cystic fibrosis during stable and exacerbations (2019) (0)
Continuous professional development: elevating thoracic oncology education in Europe (2019) (0)
Conversion to extended release tacrolimus in early post lung transplantation period : a pilot study (2018) (0)
A First Look at the Italian Registry on Pulmonary Non-Tuberculous Mycobacteria (NTM) -IRENE (2020) (0)
Validation of the Italian version of Bronchiectasis Quality of Life Questionnaire (QoL-B) (2018) (0)
Post-COVID-19 sequelae (2021) (0)
Cardiovascular Complications in Community-Acquired Pneumonia (2022) (0)
A Real-Life Evaluation of Criteria for Listing for Lung Transplant: A Single-Center, Five-Year Experience (2019) (0)
Artificial Intelligence-based CT Assessment of Bronchiectasis: The COPDGene Study. (2022) (0)
TB elimination: a dream or a reality? Key lessons from the ERS external course in Dubrovnik, Croatia (2013) (0)
The Metagenomic ‘Bacteriophagome’ in Bronchiectasis (2021) (0)
Comparison of bronchiectasis cohorts from tertiary centres in Sydney, Milan and Dundee reveal differences in severity and patterns of care (2018) (0)
Validation of a Disease Specific Severity Index for Non-Cystic Fibrosis Bronchiectasis: The BSI Index (2014) (0)
Randomized, Controlled Trial in Community-Acquired Pneumonia : A vs Oxygen Therapy To Improve Oxygenation Helmet Continuous Positive Airway Pressure (2010) (0)
COPD Risk Factors Are Linked to Specific Microbiology Patterns in Hospitalized Patients with Community-Acquired Pneumonia (2020) (0)
Pathogeneia ton loimoxeon tou anapneustikou sustematos (2010) (0)
World Bronchiectasis Day 2022 (2022) (0)
Pro-resolving and pro-inflammatory fatty acid-derived mediators in sputum of stable state bronchiectasis patients (2022) (0)
Low salivary secretory leukocyte protease inhibitor levels are related to airway Pseudomonas aeruginosa infection in Bronchiectasis. (2023) (0)
Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report (2023) (0)
Clinical phenotypes in non-cystic fibrosis bronchiectasis (NCFBE) (2014) (0)
A broad immunological screening may impact treatment in bronchiectasis patients (2019) (0)
Additional file 1: Table SA. of Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study (2016) (0)
Prevalence and Risk Factors for Enterobacteriaceae (EB) and Multidrug-Resistant EB in Community-Acquired Pneumonia (2017) (0)
S62 The microbiology of bronchiectasis exacerbations in the UK EMBARC registry and implications for prescribing in primary care: A cohort study (2021) (0)
Recommendations for Management of Nontuberculous Mycobacterial (NTM) in Lung Transplant Recipients: An International Delphi Study (0)
Duration of Antibiotic Therapy in Hospitalized Patients with Community-Acquired Pneumonia : Results from the CAPO International Cohort Study (2019) (0)
University of Dundee A comprehensive approach to lung function in bronchiectasis Radovanovic, (2018) (0)
Do Antiplatelet Medications Prevent Poor Clinical Outcomes in Patients With Community-Acquired Pneumonia? Results From the Community-Acquired Pneumonia Organization International Cohort Study (2016) (0)
Putative role of antimicrobial activity in the treatment of asthma (2007) (0)
T6 Sputum proteomics identifies mechanisms of disease severity and treatment response in bronchiectasis (2021) (0)
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet (2023) (0)
Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP) (2014) (0)
Number of bronchoalveolar cells obtained by lung lavage at various points after inoculation of mice (2011) (0)
Correction to: Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective (2020) (0)
Thrombocytosis in Patients With Severe Community-Acquired Pneumonia: Response (2010) (0)
MULTI-DRUG RESISTANT PATHOGEN SCORES PROMOTE THE OVERUSE OF ANTI-PSEUDOMONAS ANTIBIOTICS (2019) (0)
Phenotyping in bronchiectasis: Are we moving toward a personalized medicine? (2016) (0)
Plaque-related vs. plaque-unrelated cardio and cerebrovascular events (CCVE) in hospitalized patients with community-acquired pneumonia (CAP): Preliminary results from the FAILCAP study (ClinicalTrials: NCT01143155) (2014) (0)
Quinine treatment in severe Plasmodium falciparum malaria in children: A Holter monitoring (2003) (0)
What’s important for people with NTM? An EMBARC-ELF patient survey (2020) (0)
How to recognize clinical stability in hospitalized patients with community-acquired pneumonia (CAP)? (2011) (0)
Rheumatoid arthritis and bronchiectasis: A multicentre study assessing pulmonary disease severity using the bronchiectasis severity index (BSI) (2014) (0)
Quando ospedalizzare un paziente con polmonite acquisita in comunità = When do we need to hospitalize a patient with community-acquired pneumonia? (2013) (0)
Characteristics and outcomes of adults with primary ciliary dyskinesia (PCD): an EMBARC/BEAT-PCD analysis (2021) (0)
University of Dundee Characterization of bronchiectasis in the elderly Bellelli, (2016) (0)
' s response to reviews Title : Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases (0)
Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation (2018) (0)
Impact of traffic-related air pollution on pulmonary oxidative stress (2011) (0)
“Normotension” on admission to the emergency department affects outcome of patients with acute cardiogenic pulmonary edema (ACPE) (2011) (0)
University of Dundee European Respiratory Society guidelines for the management of adult bronchiectasis Polverino, (2017) (0)
Response (2021) (0)
Management of nontuberculous mycobacteria in lung transplant cases: an international Delphi study (2023) (0)
University of Southern Denmark Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community- acquired pneumonia GLIMP investigators; Bødtger, Uffe (2019) (0)
Deteriorating heath status in bronchiectasis : longitudinal data from the EMBARC registry (2021) (0)
Nontuberculous mycobacteria infection and pulmonary disease in bronchiectasis (2022) (0)
S. pneumoniae prevalence and serotypes in sputum of stable bronchiectasis (2019) (0)
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review (2023) (0)
News. (2017) (0)
Impact of neutrophil function on outcomes of community-acquired pneumonia in patients with cancer (2008) (0)
Comparison of different techniques to evaluate active neutrophil elastase in sputum of bronchiectasis and cystic fibrosis patients (2019) (0)
Clinical Characteristics and Outcomes of Patients With Community-Acquired Pneumonia—Real-Life Versus Food and Drug Administration (FDA) Trials: Results From the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study (2016) (0)
Concentrations of: IFN-γ (pg/ml) MIP-2 (pg/ml) TNF-α (pg/ml) in the bronchoalveolar lavage fluid 2 (2011) (0)
Cardiovascular Autonomic Control in Lung Transplantation Recipients (2018) (0)
Response. (2021) (0)
Acute exacerbation of COPD: application of evidence-based guidelines (2009) (0)
Respiratory failure in COVID-19: a patient's perspective and clinical cases (2021) (0)
Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE) (2018) (0)
Impact of exacerbations in the natural course of COPD (2013) (0)
P098 The “rare-exacerbator” status in adult cystic fibrosis patients (2018) (0)
S42 Sex differences in reported quality of life in bronchiectasis: an analysis of the embarc registry (2017) (0)
Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia (2020) (0)
Is lactate a prognostic factor in acute cardiogenic pulmonary edema (ACPE) (2012) (0)
Bronchiectasis in Italy: data from the national registry IRIDE (2020) (0)
Idiopathic Bronchiectasis Less Common Than Predicted: Quality Improvement Project (2013) (0)
Microbial inflammatory networks in bronchiectasis exacerbators with Pseudomonas aeruginosa. (2023) (0)
Chronic infection with non-tuberculous mycobacteria in patients with non-CF bronchiectasis: Comparison with other pathogens (2015) (0)
Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia. (2022) (0)
ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training (2018) (0)
Sputum glucose as a marker of disease severity in adult patients with cystic fibrosis (2018) (0)
The efficacy of mineral corticoid receptor antagonist, canrenone, in COVID-19 patients (2020) (0)
Characteristics of patients with hypoxemic respiratory failure due to pneumonia that respond to the application of a positive end expiratory pressure (2016) (0)
The microbiology of stable bronchiectasis: data from the EMBARC bronchiectasis registry (2021) (0)
Sex related differences in aetiology, severity and quality of life in bronchiectasis: data from the EMBARC, EMBARC-India and Australian bronchiectasis registries (2020) (0)
The Neutrophil Granule Protein Olfactomedin-4 Relates to Bronchiectasis Severity and Alters Mucociliary Clearance (0)
Non-Tuberculous Mycobacteria Testing in Bronchiectasis Patients in Europe: Data from the Embarc Registry (2020) (0)
The impact of cardiovascular events in hospitalized patients with community-acquired pneumonia (CAP): Preliminary results from the FAILCAP study (2011) (0)
Identifying patients with pneumonia due to MDR organisms coming from the community (2017) (0)
Cardiovascular Autonomic Control in End Stage Lung Disease Before Lung Transplantation (2018) (0)
Risk factors for immunosuppression in hospitalized patients coming from the community with pneumonia: a worldwide perspective (2018) (0)
Research priorities in bronchiectasis: A consensus from the European multicentre bronchiectasis audit and research collaboration (EMBARC) study group (2015) (0)
P085 Synergistic activity of colistin in combination with N-acetylcysteine against colistin-resistant Acinetobacter baumannii grown in biofilms (2018) (0)
Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia (2014) (0)
The bronchiectasis ‘bacteriophagome’ (2021) (0)
Do prognostic factors help physicians in predicting legionellosis' respiratory complications? (2011) (0)
The independent contribution of infection to long-term clinical outcomes in bronchiectasis. (2018) (0)
University of Dundee The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis Araújo, (2017) (0)
Leveraging the Omics Revolution for Nontuberculous Mycobacteria Biomarkers. (2022) (0)
Prospective comparison between chest ultrasound and X-ray in two planes in patients with suspected community-acquired pneumonia. Intermediate results (02/2011) of a prospective multicenter DEGUM-/ÖGUM-study (2011) (0)
Is etiology of non-cystic fibrosis bronchiectasis (NCFBE) a risk factor for severe exacerbation? (2014) (0)
Acute respiratory failure and severe sepsis may identify different clinical phenotypes in community-acquired pneumonia (2013) (0)
Clustering Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients According to Clinical Features (2014) (0)
Airway responsiveness to increasing concentrations of methacholine at various points after inoculati (2011) (0)
International Guideline concordance of empiric antibiotic use in community-acquired pneumonia (2020) (0)
P104 Prevalence, clinical characteristics and outcomes of patients referred to an adult cystic fibrosis centre from pulmonary clinics (2018) (0)
Clinical failure in hospitalized patients with community acquired pneumonia (CAP): Preliminary results from the FAILCAP study (2011) (0)
Validation of the 3CPO-score in a prospective cohort of Acute Cardiogenic Pulmonary Edema (ACPE) patients (2011) (0)
Real life NIV use in ACPE: Preliminary results of a multicentric study on the treatment of ACPE in the Emergency Department (2010) (0)
Should health care systems and health care providers implement a new pathway for hospitalized patients with community-acquired pneumonia? (2012) (0)
Clinical characteristics and disease severity of adults with cystic fibrosis with at least one residual function mutation (2018) (0)
How to diagnose and quantify bronchiectasis for clinical studies using chest imaging (2018) (0)
Cardiovascular autonomic alterations and severity of the disease in community-acquired pneumonia (2013) (0)
Respiratory involvement in Fabry disease (2013) (0)
Management of respiratory outpatients: A retrospective descriptive analysis (2019) (0)
Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review (2023) (0)
Neutrophil elastase is correlated with disease severity in a cohort from Southern Europe (2020) (0)
Correlation of Obesity With Outcomes in Hospitalized Patients With Community-Acquired Pneumonia: Results From the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study (2016) (0)
Alpha1-Antitrypsin Inherited Variants in Patients With Bronchiectasis. (2023) (0)
Aspiration Risks Factors, Microbiology and Empiric Antibiotics for Patients Hospitalized with Community Acquired Pneumonia (2020) (0)
A 61-year-old female with chronic cough and purulent sputum (2013) (0)
In vitro activity of colistin in combination with N-acetylcysteine against Pseudomonas aeruginosa (2018) (0)
NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE : CURRENT STATE OF KNOWLEDGE AND FUTURE DIRECTIONS The two symposia (2017) (0)
Outcomes of patients undergoing treatment for non-tuberculous mycobacteria lung disease (2019) (0)
COVID-19 follow-up programmes across Europe: an ERS END-COVID CRC survey (2022) (0)
Pneumonia: how important are local epidemiology and smoking habits? (2016) (0)
YOU DON’T FIND WHAT YOU DON’T LOOK FOR: PREVALENCE OF IMMUNODEFICIENCY IN PATIENTS WITH CYSTIC FIBROSIS USING A BROAD IMMUNOLOGICAL SCREENING (2020) (0)
Quality of care in bronchiectasis using the European Respiratory Society Guidelines as a reference standard- data from the EMBARC registry (2021) (0)
Anaerobic Coverage is Not Needed for Patients With Chronic Aspiration Hospitalized With Community-Acquired Pneumonia (2017) (0)
Salivary SLPI and disease severity in bronchiectasis (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stefano Aliberti?

Stefano Aliberti is affiliated with the following schools:

Stefano Aliberti's Academic­Influence.com Rankings

Stefano Aliberti's Degrees

Similar Degrees You Can Earn

Why Is Stefano Aliberti Influential?

Stefano Aliberti's Published Works

Published Works

What Schools Are Affiliated With Stefano Aliberti?

Stefano Aliberti's AcademicInfluence.com Rankings